



ASX ANNOUNCEMENT

25 November 2024

Clarification Announcement

Melbourne, Australia – Opyl Limited (ASX: OPL), released an announcement titled “Opyl Signs Service Level Agreement with Southern Clinical Development Consulting (**Southern CDC**)”, dated 21 November 2024 (**Announcement**).

With regards to the Announcement the Company provides the following additional information:

- the TrialKey platform provides Southern CDC with comprehensive, data-rich reports with projects starting from AUD \$5000;
- there are no material conditions that need to be satisfied before Southern CDC adopts our TrialKey platform;
- there is no minimum number of reports commissioned under the agreement; and
- there is no other material information relevant to assessing the impact of the agreement with Southern CDC on the price or value of the Company's securities.

This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice.averion@opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

Opyl Limited
Level 10, 99 Queen Street, Melbourne VIC 3000
ABN: 71 063 144 865
www.opyl.ai